Is ARRY a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,043 people get ARRY articles and Market Currents by email alert.

Get email alerts on ARRY »

HEADLINES:

Array BioPharma's CEO Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)
Thu, May 16
Part 3: Will Array BioPharma Become A Late Stage Biopharmaceutical Company?
C.R. Jackson • Thu, May 16 • 1 Comment
Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting

PR Newswire (Wed, 8:00AM)
Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stock
Emerging Equities • Wed, May 15
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 4 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference

PR Newswire (May 8, 2013)
Array BioPharma's CEO Discusses Q3 2013 Results - Earnings Call Transcript
Tue, May 7
Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Scott Matusow • Tue, May 7 • 8 Comments
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013

PR Newswire (May 6, 2013)
Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer

PR Newswire (May 6, 2013)
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2013 On May 6, 2013

PR Newswire (Apr 29, 2013)
Array's Up-Coming Value Enhancing Catalysts
Veziris Ventures • Wed, Apr 17 • 2 Comments
Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop

PR Newswire (Apr 4, 2013)
Array BioPharma: An Exciting Year Ahead
BPD Research • Thu, Mar 28 • 11 Comments
Piper Jaffray Likes Array, Should You?
Brian L. Wilson • Mon, Mar 25
Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer

PR Newswire (Mar 21, 2013)
Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology

PR Newswire (Mar 5, 2013)
Array BioPharma To Present At The Cowen Annual Health Care Conference

PR Newswire (Feb 26, 2013)
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference

PR Newswire (Feb 8, 2013)

Array BioPharma: An Exciting Year Ahead
BPD Research • Thu, Mar 28 • 11 Comments

Part 3: Will Array BioPharma Become A Late Stage Biopharmaceutical Company?
C.R. Jackson • Thu, May 16 • 1 Comment
Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stock
Emerging Equities • Wed, May 15
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 4 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Array's Up-Coming Value Enhancing Catalysts
Veziris Ventures • Wed, Apr 17 • 2 Comments
Array BioPharma: An Exciting Year Ahead
BPD Research • Thu, Mar 28 • 11 Comments
Piper Jaffray Likes Array, Should You?
Brian L. Wilson • Mon, Mar 25
Array BioPharma: A Diamond For The Long Term
Jorge Aura • Thu, Oct 25, 2012 • 1 Comment
Can Array BioPharma's Breakout Run Hold Or Continue?
M. E. Garza • Mon, Jul 23, 2012 • 2 Comments
Array Biopharma Inc. Offers Value And Upside Potential With Its Many Drugs
Roy Manning III • Mon, Apr 2, 2012
Array Represents a Great Opportunity for Very Patient Investors
Prohost Biotech • Wed, Aug 17, 2011 • 3 Comments
Array BioPharma's Cancer Deal Expands Its Coffers
M. E. Garza • Tue, Aug 9, 2011
Bottom Bounce for Array BioPharma
M. E. Garza • Wed, Jun 29, 2011
Array Biopharma: A Wall Street Anomaly
Ohad Hammer • Mon, Oct 4, 2010

Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Scott Matusow • Tue, May 7 • 8 Comments
Synta: Share Price Not Reflecting Ganetespib Value Proposition
Poonam A. Arora • Tue, Jan 15 • 6 Comments
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Ohad Hammer • Mon, Dec 24, 2012 • 11 Comments
Is Telik A Good Buy After Increasing 24% In One Day?
C.R. Jackson • Wed, Dec 12, 2012 • 1 Comment
What Is So Exciting About MEI Pharma?
C.R. Jackson • Fri, Nov 16, 2012 • 2 Comments
ASH 2012 Preview: Top Picks For Upcoming Blood Cancer Meeting
Ohad Hammer • Mon, Nov 12, 2012 • 2 Comments
VIX - Options Volatility Sonar: Friday Recap
Erick McKitterick • Sat, Nov 3, 2012 • 9 Comments
5 Small Cap Stocks Under $5 With Short Covering
Kapitall • Wed, Oct 24, 2012
2 Pharma Companies To Consider During Tuesday's Session
Matt Schilling • Tue, Jul 31, 2012 • 6 Comments
Synta - The Signal Looks Real
Ohad Hammer • Tue, Jul 10, 2012 • 5 Comments
Winners Of ASCO 2012
Ohad Hammer • Mon, Jun 11, 2012 • 12 Comments
Drugs To Watch At ASCO 2012
Ohad Hammer • Tue, May 29, 2012 • 15 Comments
Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 1
StockPandit • Thu, May 24, 2012 • 5 Comments
Biotech-Focused Baker Bros. $3.7B Fund Bought These 3 Big Winners And Sold Others In Q1
GuruFundPicks • Thu, May 17, 2012 • 9 Comments
Top Micro Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 12 Comments
Monday Options Recap: Cisco, Intel Risk Reversal
Frederic Ruffy • Mon, Apr 9, 2012
3 Names That Forged New 52-Week Highs On Double Volume To Track On Monday
Kinetic Investments • Fri, Apr 6, 2012
Galena Biopharma: Risk Mitigated After Financing
The Swiss Trader • Thu, Apr 5, 2012 • 1 Comment
Upcoming ASCO Meeting Could Move These Stocks
Brian Nichols • Wed, Apr 4, 2012 • 6 Comments
Threshold Scores Big With Pancreatic Cancer Data
Ohad Hammer • Mon, Mar 5, 2012 • 9 Comments

Array BioPharma's CEO Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)
Thu, May 16
Array BioPharma's CEO Discusses Q3 2013 Results - Earnings Call Transcript
Tue, May 7
Array BioPharma's CEO Discusses F2Q2013 (Qtr End 12/31/12) Results - Earnings Call Transcript
Tue, Feb 5 • 1 Comment
Array BioPharma's CEO Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript)
Tue, Jan 8
Array Biopharma's CEO Presents at Lazard Annual Healthcare Conference (Transcript)
Tue, Nov 13, 2012
Array Biopharma Management Discusses Submitted ASH Abstracts - (Transcript)
Wed, Nov 7, 2012
Array BioPharma's CEO Discusses F1Q2013 Results - Earnings Call Transcript
Tue, Oct 30, 2012
Array BioPharma's CEO Presents at UBS 2012 Global Life Sciences Conference (Transcript)
Thu, Sep 20, 2012
Array BioPharma's CEO Presents at Morgan Stanley Healthcare Conference - Transcript
Mon, Sep 10, 2012
Array BioPharma's CEO Discusses F4Q2012 Results - Earnings Call Transcript
Tue, Aug 14, 2012
Array BioPharma CEO Discusses F1Q2011 Results - Earnings Call Transcript
Tue, Nov 9, 2010
Array BioPharma Inc. F4Q10 (Qtr End 06/30/10) Earnings Call Transcript
Tue, Aug 10, 2010
Array BioPharma Inc. F3Q 2010 (Qtr End 06/30/2010) Earnings Call Transcript
Tue, May 4, 2010
Array BioPharma Inc. F2Q10 (Qtr End 12/31/09) Earnings Call Transcript
Tue, Feb 2, 2010
Array BioPharma F2Q09 (Qtr End 12/31/08) Earnings Call Transcript
Tue, Feb 3, 2009
Array BioPharma F1Q09 (Qtr End 09/30/08) Earnings Call Transcript
Tue, Nov 4, 2008
Array BioPharma, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript
Tue, Sep 2, 2008
Array BioPharma, Inc., Q3 Earnings Call Transcript
Tue, May 6, 2008
Array BioPharma Inc. Q2 2008 Earnings Call Transcript.
Tue, Feb 5, 2008

Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting

PR Newswire (Wed, 8:00AM)
Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference

PR Newswire (May 8, 2013)
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013

PR Newswire (May 6, 2013)
Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer

PR Newswire (May 6, 2013)
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2013 On May 6, 2013

PR Newswire (Apr 29, 2013)
Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop

PR Newswire (Apr 4, 2013)
Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer

PR Newswire (Mar 21, 2013)
Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology

PR Newswire (Mar 5, 2013)
Array BioPharma To Present At The Cowen Annual Health Care Conference

PR Newswire (Feb 26, 2013)
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference

PR Newswire (Feb 8, 2013)
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013

PR Newswire (Feb 4, 2013)
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013

PR Newswire (Jan 29, 2013)
Array BioPharma To Present At The Annual J.P. Morgan Healthcare Conference

PR Newswire (Dec 27, 2012)
Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting

PR Newswire (Dec 10, 2012)
Array BioPharma Announces Exercise And Closing Of Underwriters' Over-Allotment Option

PR Newswire (Dec 5, 2012)
Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference

PR Newswire (Nov 15, 2012)
Movers & Shakers: Friday’s biggest movers; Apple catches a break

at MarketWatch.com (Nov 9, 2012)
Array BioPharma Announces Pricing Of Public Offering Of Common Stock

PR Newswire (Nov 9, 2012)
Array BioPharma Announces Proposed Public Offering Of Common Stock

PR Newswire (Nov 8, 2012)
MEK162 Registration Path Announced

PR Newswire (Nov 8, 2012)

ARRY vs. ETF Alternatives

Company Description

We are a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed... More

Sector: Services

Industry: Research Services

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Monday, May 6, 4:07 PM Array Biopharma (ARRY): Q1 EPS of -$0.19 misses by $0.05. Revenue of $10M misses by $4.54M. (PR) Comment! [Earnings, Breaking News]
Monday, May 6, 12:10 AM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Sunday, May 5, 5:35 PM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
Thursday, April 4, 8:53 AM Array BioPharma's (ARRY +2.25%) ARRY-520 drug for multiple myeloma showed encouraging clinical activity in two trials of patients who had received heavy previous treatments and had "limited therapeutic options." The median survival rates was 19 months and the overall response rate 16%, similar to other recently approved products. ARRY-520 was also well tolerated. (PR) Comment! [Healthcare]
Wednesday, March 27, 6:13 PM Array Biopharma (ARRY) says it's entered into a sales agreement for an at-the-market share offering with Cantor Fitzgerald. Subject to the terms and conditions, ARRY] may from time to time issue and sell through Cantor up to $75M in stock. Shares -5% AH. Comment! [On the Move, Healthcare]
Wednesday, March 27, 5:49 PM After-hours top gainers, as of 5:15 p.m.: GBX +3%. GNW +3%. LCC +3%. MATX +1.4%. SU +1.1%.
After-hours top losers: ARRY -12%. RHT -9%. FIVE -7%. ESI -6%. PVH -5%. Comment! [On the Move]
Monday, March 25, 10:52 AM Array BioPharma (ARRY +11%) gets a big boost from an upgrade to Overweight at Piper Jaffray this morning, pushing the stock near a 5-month high. Piper says the company has a host of potentially positive study data due out later this year, and several partnering opportunities in FY13 that could bring in non-dilutive funding. This is encouraging, as the company already finished 2012 with $110M of cash, which the firm estimates would get ARRY through mid-2014. Comment! [Healthcare, On the Move]
Monday, February 4, 5:15 PM More on Array Biopharma (ARRY): Q2 beats as per share losses come in less-than-expected. CEO Ron Squarer notes strong progress across its pipeline, with Novartis saying it's set to begin Phase 3 trials of MEK162, and AstraZeneca set to start Phase 3 trials with selumetinib in non-small cell lung cancer during the second half of 2013. Comment! [Healthcare, Earnings]
Monday, February 4, 4:53 PM Array Biopharma (ARRY): FQ2 EPS of -$0.1 beats by $0.04. Revenue of $18.4M beats by $1.88M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 4, 12:10 AM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
Sunday, February 3, 5:35 PM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
Wednesday, November 21, 2012, 5:39 PM After-hours top gainers, as of 5:15 p.m.: IMGN +7.1%. SHLD +4.2%. ARRY +3.4%. IDIX +3.0%. VRTX +2.5%.
After-hours top losers: MRGE -9.0%. CVGI -7.1%. GORO -6.6%. HW -6.3%. QLIK -4.5%. 2 Comments [On the Move]
Friday, November 9, 2012, 10:39 AM Drug developer Array BioPharma (ARRY -12.3%) slides after pricing an 18M share secondary offering at $3.65 per share, a 10% discount to yesterday's close. The company had 95.4M shares outstanding as of October, which would make the sale nearly a 19% dilution to its float. Comment! [Healthcare, On the Move]
Friday, November 9, 2012, 9:10 AM Premarket gainers: ZIP +27%. KYAK +26%. LGF +9%. ENR +8%. PSTI +8%. IGT +7%. WCRX +6%. ISIS +5%.
Losers: GRPN -23%. MTG -15%. ARRY -12%. PGRX -12%. SPRD -10%. JCP -8%. PVR -6%. CPIX -5%. DIS -5%. 1 Comment [On the Move]
Friday, August 31, 2012, 4:15 PM Array BioPharma (ARRY) announces that Francis Bullock, Ph.D., and Kevin Koch, Ph.D., have decided not to stand for reelection to its Board of Directors and that David Snitman, Ph.D., intends to resign from the Board. Comment! [Healthcare]

Ryan Mallory
My Swing Trading Watch-List for Long Setups | $LULU $KWK $AEGR $EW $ARRY and others. http://bit.ly/RCo0Zb
12/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Lazy Trade Long & Short: $ARRY & $SXC http://bit.ly/QHACwr
12/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

johnjail
Increased stake in ATRS, AMPE, ARRY. I'm thinking about for a speculative position in CUR at current 0.75$ is mouthwatering...
8/10/12
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: DRRX man! Nobody's talking about it. They will.
8/10/12
• !Report Abuse
johnjail: nice pipeline and nice last quarter :) but I didn't find the cash they have and the burn rate. at that price seems to be interesting
8/11/12
• !Report Abuse
Add a reply...

140 characters

Roy Manning III
ARRY is a good buy. Expecting $20 million in milestone payments by end of year. Payments from partners keep this stock profitable.
5/8/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

whitehead1
I am buying ARRY before earning. I think it has very good upside after earning report for a trade.
4/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
2/14 Video Watchlist $CEDC $UPIP $AVNW $ACW $SPF $COCO $AFFY $ARRY $XLS $NQ $CALD http://bit.ly/zLJwPb
2/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Eric Stalee
Does anyone have knowledge on ARRY?
12/20/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

djw876
Array (ARRY) Biopharma - another earnings surprise +67% surprise. RTK - WTF. LXRX - in for the long hall, ALSE - dopamaine
11/2/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sdhir
ARRY CEO bought $57K worth from open market recently. http://bit.ly/kbUDus
5/16/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
ARRY, SNTS, VNDA, DCTH, EXAS, IMMU, MITI, MNKD, ONXX, PCYC, SNTA, ZIOP + others sold off at close, but quickly recovered lost ground. Hmmm.
12/20/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

johnjail
Increased stake in ATRS, AMPE, ARRY. I'm thinking about for a speculative position in CUR at current 0.75$ is mouthwatering...
8/10/12
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: DRRX man! Nobody's talking about it. They will.
8/10/12
• !Report Abuse
johnjail: nice pipeline and nice last quarter :) but I didn't find the cash they have and the burn rate. at that price seems to be interesting
8/11/12
• !Report Abuse
Add a reply...

140 characters

ARRY Array BioPharma Inc.

ARRY

Array BioPharma Inc.